Genfit S.A. (MUN:XUPB)

Market Cap	466.08M +168.2%
Revenue (ttm)	45.13M -43.9%
Net Income	-38.76M
EPS	-0.81
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	8.80
Previous Close	7.75
Day's Range	8.80 - 8.80
52-Week Range	5.05 - 8.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 2, 2026

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 188
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: XUPB

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Mar 11, 2026

Data Sources Report a data error